NANJING, China, April 30 /Xinhua-PRNewswire/ -- Simcere Pharmaceutical Group (NYSE: SCR), a leading manufacturer and supplier of branded generic pharmaceuticals in the rapidly growing Chinese marketplace, announced today that it intends to release its 2007 first quarter earnings on Tuesday, May 15, 2007, after market closing. Simcere's management will host an earnings conference call to discuss the company's 2007 first quarter results on Tuesday, May 15, at 8 p.m. Eastern Time (Wednesday, May 16, at 8 a.m. Beijing/Hong Kong time).
To access the conference call, please dial:
US toll free dial in number: 866-713-8310
US toll dial in number: 617-597-5308
HK toll dial in number: +852-3002-1672
Please ask to be connected to Simcere's Q1 2007 Earnings Call and provide the following passcode: Simcere. Simcere also will broadcast a live audio webcast of the conference call. The broadcast will be available by visiting the “Investor Relations” section of the Company's Web site at http://www.simcere.com .
Following the earnings conference call, an archive of the call will be available by dialing:
US toll free dial in number: 888-286-8010
International dial in number: 617-801-6888
The passcode for replay participants is: 73035007. The conference call also will be archived at http://www.simcere.com for seven days following the earnings announcement.
About Simcere Pharmaceutical Group
Simcere Pharmaceutical Group is a leading manufacturer and supplier of branded generic pharmaceuticals in the rapidly growing China market. It currently manufactures and sells 35 pharmaceutical products including antibiotics, anti-cancer medication and anti-stroke medication and is the exclusive distributor of three additional pharmaceuticals that are marketed under its brand names. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, osteoporosis and infectious diseases. For more information about Simcere Pharmaceutical Group, please visit http://www.simcere.com .
For investor and media inquiries, please contact:
In China:
Eric Wang Lam Cheung
Vice President, Investor Relations
Simcere Pharmaceutical Group
Tel: +86-25-8556-6666 x8898
Email: eric.cheung@simcere.com
In the United States:
Ashley Zandy
Brunswick Group LLC
Tel: +1-212-333-3810
Email: ir@simcere.com
